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Abstract
We have characterized nine mcr-1-harboring plasmids from clinical Escherichia coli isolates
previously described in Argentina and Canada. Three of these plasmids carried a mcr-1-var-
iant called here mcr-1.5. All these E. coli isolates were not clonally related and were recov-
ered in different years and locations. However, their mcr-1-harboring plasmids showed high
identity among them and to others characterized in other countries, which strongly suggests
that this plasmid-type is playing an important role in spreading this mechanism of resistance
to polymyxins.
Introduction
Since the first description of MCR-1, a plasmid-encoded phosphoethanolamine transferase, in
November, 2015, in China [1], this mechanism of polymyxin resistance was detected around
the world in enterobacterial isolates recovered from animals, environment, food samples and
humans [2]. MCR-1-producing Escherichia coli was the most common species described in the
literature, mainly of polyclonal origin. Similar plasmids harboring mcr-1 gene (pMCRs) were
found elsewhere, belonging to replicon types IncI2, IncHI2 and IncX4, supporting the notion
that horizontal transfer constitutes the major dissemination route of mcr genes [3,4].
Very recently a new mcr allele, mcr-2 (76.7% nucleotide identity with mcr-1), was character-
ized in Belgium [5], as well as new variants of mcr-1 (mcr-1.2 in Italy and mcr-1.3 and -1.6 in
China) [6–8].
The first gram-negative mcr-1-positive bacteria described in the Americas were E. coli iso-
lates recovered in Argentina [9] and Canada [10]. Nine multidrug resistant E. coli were
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recovered from clinical human specimens in six Argentinian hospitals from three cities
between July 2012 and January 2016. These isolates were part of a larger sample of 87 colistin
resistant Gram-negative bacilli collected between 2008 and 2016, which were screened for the
presence of mcr-1 by PCR [9]. The Canadian isolate was recovered from a gastrostomy tube
site and rectum of a patient hospitalized in Ottawa, Ontario, Canada, in 2011, who previously
received health care in Egypt [10,11]. This isolate was an OXA-48- and CTX-M-15-producing
multidrug-resistant E. coli. As part of a database of ~1600 Canadian bacterial whole-genome
sequences, this was the only clinical isolate of three mcr-1-positive E. coli initially found in
Canada after screening of this database [10]. Here, we describe the molecular characteristics of
IncI2 pMCRs recovered from these clinical E. coli isolates from Argentina and Canada, as well
as a new variant of the mcr-1 gene. We also compare them with other IncI2 mcr-harboring
plasmids described elsewhere, strengthening the notion of this replicon-type as one of the
main mcr-disseminator.
Materials and methods
The first ten mcr-1 isolates described in the Americas were included in this study, nine from
Argentina (E. coli isolates M15049, M15224, M17056, M17059, M19241, M19242, M19441,
M19736 and M19855) and one from Canada (E. coli GN775) [9–11]. Susceptibility profiles
were obtained by Etest (bioMe´rieux) with the exception of colistin (broth dilution) and the
results interpreted by the 2016 Clinical and Laboratory Standards Institute guidelines [12]
except for colistin and tigecycline, interpreted according to the European Committee on Anti-
microbial Susceptibility Testing guidelines [13]. E. coli clinical isolates were genotyped by
MLST [14]. Plasmid profiles of these clinical isolates were obtained by pulsed-field gel electro-
phoresis analysis of S1 nuclease-digested DNA (S1-PFGE) [15]. The ones carrying the mcr-1
gene were identified and their sizes estimated by S1-PFGE followed by Southern blot analysis
using a specific mcr-1 probe [15]. Plasmid content of each isolate was extracted with the QIA-
prep Spin miniprep kit (Qiagen) and used for transformation assays in chemically competent
E. coli TOP10 (Life Technologies; colistin MIC of 0.016 μg/ml). mcr-1-transformant strains
were selected using Luria-Bertani agar plates supplemented with colistin (1 μg/ml), and con-
firmed by PCR. pMCRs were then extracted from transformant E. coli strains using the Qiagen
Large-Construct kit (Qiagen) and sequenced using Illumina’s MiSeq system. The obtained
contigs were assembled using CLC Genomics Workbench software (CLC bio, Qiagen). Gaps
were filled by PCR amplification and Sanger sequencing. Open reading frames (ORFs) were
annotated using the RAST server (rast.nmpdr.org) followed by manual comparative curation
and determination of sequence similarity using the BLAST web server. Alignments with other
IncI2 pMCRs were performed by using the BRIG tool [16].
The sequences of the plasmids reported here have been deposited in GenBank under
accession numbers KY471307 (pMCR-GN775), KY471308 (pMCR-M15049), KY471309
(pMCR-M15224), KY471310 (pMCR-M17059), KY471311 (pMCR-M19241), KY471312
(pMCR-M19242), KY471313 (pMCR-M19441), KY471314 (pMCR-M19736) and KY471315
(pMCR-M19855)
Results and discussion
Table 1 shows the susceptibility profiles of E. coli clinical isolates. Colistin MICs ranged from 4
to 16 μg/ml. All isolates were susceptible to amikacin and tigecycline. With the exception of
the Canadian isolate (OXA-48 and CTX-M producer) [11] and 4 Argentinian E. coli (CTX-M
producers) [9], the isolates were generally susceptible to ß-lactams. Conversely, most of the
isolates were resistant to quinolones and tetracycline. By MLST all the clinical isolates
mcr-1-carrying plasmids from polyclonal clinical Escherichia coli from Argentina and Canada
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belonged to different sequence types (ST) (Table 1). Compared to the E. coli MLST database
(http://mlst.ucc.ie/mlst/dbs/Ecoli; 7,412 STs; last accessed June 5, 2017), none of the STs
assigned to the Argentinian isolates included in this work were found among the eight entries
previously reported from Argentina, while ST624, which was assigned to the Canadian isolate
GN775, was found in two entries reported from Canada. ST410, which was assigned to isolate
M19441, was defined as a hyperepidemic clone and founder of the widely disseminated clonal
complex 23 (CC23) [17]. This clone was also previously found to carry mcr-1 as well as
blaCTX-M genes in isolates recovered from a turkey hen meat sample in Germany [18] and
from a human blood culture in Brazil [19]. In these two last cases, mcr-1 gene was located on
the bacterial chromosome [18] and on an IncX4 plasmid [19]. There is evidence that E. coli
ST410 has been successful for interspecies transmission between food-producing animals,
wildlife, humans, companion animals and the environment, increasing the risk of becoming a
successful pandemic clone [20].
S1-PFGE showed a varied plasmid content in all the clinical isolates but Southern blot with
mcr-1 probe showed that the pMCRs were very similar in size (~60 kb) (Fig 1).
Nine mcr-1-transformant strains were obtained (8 from Argentina and 1 from Canada; no
mcr-1 transformant strain was achieved for E. coli M17056). Colistin was the only antimicro-
bial drug for which all transformant isolates showed reduced susceptibility or resistance (MICs
of 2 to 4 μg/ml). Comparison of the transferred mcr genes with the original mcr-1 [1] showed
that 3 of the Argentinian isolates (M15049, M17059 and M19241, recovered from two hospi-
tals) had the same missense point mutation in position 1,354 resulting in a H452Y change of
the MCR protein. Other three new MCR-1 variants were recently published, MCR-1.2, MCR-
1.3, and MCR-1.6 [6–8]. Other unpublished MCR-1 variants were also found in the Genbank
database (Table 2). We noticed that one of them, called MCR-1.5 found in an E. coli isolated
from human urinary tract sample in Argentina (GenBank accession number KY283125), had
the same H452Y amino acid change described in our study. To avoid future confusions with
the nomenclature, we called the new variant described here as MCR-1.5.
All plasmids included the conserved 2,607 bp DNA segment containing mcr (mcr-1 or mcr-
1.5) and pap2 genes [21] with slightly different genetic environments (Fig 2). Two isolates pre-
sented the change TAAAAT instead of TATAAT at -10 box promoter region described previ-
ously [22]. The three isolates carrying the new variant mcr-1.5/pap2 (M15049, M17059 and
M19241) had this DNA segment flanked by 2 copies of ISApI1 in the same orientation (Fig 2)
but the characteristic 2 bp target site duplications (TSD) were not found [21].
This composite transposon was not described very often (usually only one copy, if any, of
ISApI1 is present beside mcr-1) [4,20,23] and would be responsible for the chromosomal inte-
gration of mcr-1 in E. coli [18,23–25]. ISApI1 was not present in pMCRs from the other 5
Argentinian and the Canadian isolates (Fig 2). The corresponding inverted repeat right and
left (IRR and IRL) were also absent in those plasmids. However, the mcr-pap2 element was
found in a similar location, between top (encoding a DNA topoisomerase III) and nikB (relax-
ase) genes (Fig 2), like in pHNSHP45 and other IncI2 plasmids, suggesting a hot spot for the
insertion of this transposon in this plasmid-type. In these 6 isolates where ISApI1 was absent,
the mcr-pap2 element was flanked by a conserved trinucleotide (5’-ATA-3’), a sequence found
immediately downstream of the IRR of ISApl1 in both composite transposons and single-copy
ISApl1 [21]. The absence of ISApI1 in some pMCRs described here and elsewhere could be
explained by its mobilization, transposing the mcr-pap2 structure to conjugative plasmids with
a subsequent loss of ISApI1 copies following integration, as postulated before [21,26,27].
Based on the predicted structure of MCR-1 [1,28] and the crystal structure of the catalytic
domain [29], the amino acid change H452Y found in MCR-1.5 was located between helix α6
and sheet β10 (Fig 3).
mcr-1-carrying plasmids from polyclonal clinical Escherichia coli from Argentina and Canada
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Fig 1. Identification of mcr-1-harboring plasmids. (A) S1 nuclease-pulsed–field gel electrophoresis plasmid profiles. (B) Autoradiograph
of gel A hybridized with mcr-1 probe. Yellow arrowheads indicate positive bands. Ladder, reference standard Salmonella enterica serotype
Braenderup strain H9812 restricted with XbaI (sizes are given in kilobases).
https://doi.org/10.1371/journal.pone.0180347.g001
Table 2. mcr-1 variants available at the GenBank database (updated to June 9, 2017).
Variant Amino
acid
change
Species Country Accession number Reference
mcr-1 - E. coli China KP347127 [1]
mcr-
1.2
Q3L K.
pneumoniae
Italy KX236309 [6]
mcr-
1.3
I38V E. coli China KU934208 [7]
mcr-
1.4
D440N E. coli China KY041856 Unpublished
mcr-
1.5
H452Y E. coli Argentina KY283125KY471308KY471310KY471311 Unpublished
This work
mcr-
1.6
R536H S.
Typhimurium
China KY352406 [8]
mcr-
1.7
A215T E. coli China KY488488 Unpublished
mcr-
1.8
Q3R E. coli Brunei KY683842 Unpublished
https://doi.org/10.1371/journal.pone.0180347.t002
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Like MCR-1, a H452 was found in MCR-2, which showed some amino acid changes sur-
rounding this position. Homology comparison with the phosphoethanolamine transferases
(PAE) LptA from Neisseria meningitidis and EptC from Campylobacter jejuni showed an argi-
nine (position 440) and glutamine (position 415), respectively, corresponding to the Y452 in
MCR-1.5. A tyrosine residue was also observed at this position in the PAE of Enhydrobacter
aerosaccus (WP_007116571.1), Paenibacillus sophorae (WP_036596266.1) and Dichelobacter
nodosus (WP_041729850.1) [1]. A recent evolutionary analysis grouped MCR-1 with those of
E. aerosaccus, P. sophorae and D. nodosus, and very close to the PAE of Moraxella catarrhalis
(subclade I), while LptA was grouped in a second subclade of PAEs [30]. The lack of differ-
ences in colistin resistance levels observed between MCR-1- and MCR-1.5-transformant
strains would suggest that the amino acid change found in MCR-1.5 is not affecting its PAE
activity.
Full sequences of these nine pMCR showed a GC content ranging between 42.3% and 43%.
As showed by S1-PFGE and Southern blot analysis, their sizes were similar and all belonged to
the IncI2 incompatibility group (Fig 4).
pMCRs of Argentinian origin were highly similar, with a genetic identity ranging between
87.2% and 99.8%. Six of them (from clinical isolates M15049, M15224, M17059, M19241,
Fig 2. Genetic environment of mcr-1 variants. Genes and their corresponding transcriptional orientations
are indicated by horizontal broad arrows. Open reading frames encoding hypothetical proteins are
represented by grey triangles. Vertical red lines represent ISApI1 inverted repeats (IRL and IRR).
https://doi.org/10.1371/journal.pone.0180347.g002
Fig 3. Alignment of the deduced amino acid sequence of MCR-1 and MCR-1.5 with other related phosphoethanolamine transferases.
Position 452 (His in MCR-1; Tyr in MCR-1.5) is indicated in red between helix α6 (blue) and sheet β10 (green).
https://doi.org/10.1371/journal.pone.0180347.g003
mcr-1-carrying plasmids from polyclonal clinical Escherichia coli from Argentina and Canada
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M19242, and M19441) showed maximum genetic similarities to plasmids pABC149-mcr-1
(GenBank accession no. KX013538), isolated from a pathogenic human E. coli in the United
Arab Emirates [31], and pHNSHP45 (KP347127) the first reported pMCR [1]. The other 2
pMCRs (from M19736 and M19855) were more similar to plasmid pECJS-61-63 (KX084393)
from an E. coli recovered in China (95.1% identity; 84.6% identity with pHNSHP45). The
Canadian pMCR (from GN775) was the most divergent, with an overall 83% identity with the
Argentinian plasmids, 80.3% identity with pHNSHP45, and a maximum genetic identity with
plasmid pECJS-61-63 (91%). All backbone and transfer genes in the pMCRs characterized in
this study were highly conserved. Differences were mainly due to the presence of insertion
sequences (e.g. ISApI1 in three Argentinian plasmids flanking the mcr-pap2 structure, or some
transposases downstream of repA in the Canadian pMCR), absence of open reading frames
encoding for hypothetical proteins and reorganization of the pilV shufflon (Fig 4). Same kind
of similarities and variations were observed in the alignment of different IncI2 plasmids, har-
boring or not mcr-1 gene, with the ones described in our study (Fig 5).
In Argentina, mcr spread would be due to the increased use of polymyxins against emer-
gent, highly resistant clinical pathogens such as KPC-producing Enterobacteriaceae or
extremely drug-resistant Acinetobacter baumannii [9], which could create selective pressure in
Fig 4. Comparison of pMCRs described in this study. Arrows indicate the following predicted open reading frames: conjugation, stability, and accessory
genes (green, yellow), antimicrobial resistance genes (mcr-1 in red; mcr-1.5 in dark red), transposon-related genes (blue), hypothetical proteins (grey),
shufflon segments (black), and replicase genes (brown). The light blue-shaded areas show regions with ~100% identity among the compared structures;
grey-shaded areas, 50% identity or lower.
https://doi.org/10.1371/journal.pone.0180347.g004
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Argentinian nosocomial environments. Data from the WHONET-Argentina Resistance Sur-
veillance Network showed that, in 2015, the prevalence of nosocomial E. coli and K. pneumo-
niae non-susceptible to colistin (resistance plus intermediate categories) was 2.2% (1.1% for
each intermediate resistance and resistance) and 10.3% (0.2% for intermediate resistance and
10.1 for resistance), respectively [32]. However, a recent report describes a broad dissemina-
tion of mcr-1 gene in E. coli recovered from healthy poultry in Argentina, suggesting an
Fig 5. Sequence alignment of IncI2-type mcr-1-bearing plasmids. pHNSHP45 was used as a reference to compare with the pMCRs described here and
with other IncI2 plasmids. The outer circle with red arrows indicates annotation of the reference sequence. Gaps in the inner circles are missing regions when
compared with the reference. Plasmids characteristics are included in Table 3.
https://doi.org/10.1371/journal.pone.0180347.g005
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important source of this colistin resistant microorganism since at least 2013 [33]. In contrast,
in countries like Canada where colistin is not commonly used in clinical therapy schemes, low
detection of this mechanism in clinical isolates [34] was the result of ‘imported’ pathogens by
patients hospitalized in countries where the mcr gene is more common to be found (e.g.
China) [35], or where it was detected but its prevalence is unknown (e.g. Egypt) [11,36].
The worldwide emergence of colistin resistant bacteria without any prior clinical colistin
exposure could be considered a consequence of polymyxins use in veterinary medicine [37–
39] and as promoter factors in the agriculture and food production sectors [1,33,37–40].
Table 3. List of IncI2 plasmids aligned in Fig 5 against the pMCRs described in this study.
Fig 5
#
Plasmid name Species Length (bp) Accession # Country mcr-variant
1 pHNY2 Escherichia coli 65358 KF601686 China No
2 pHNLDH19 Escherichia coli 62194 KM207012 China No
3 pHN1122-1 Escherichia coli 62196 JN797501 China No
4 pSTH21 Salmonella enterica 62139 LN623683 Hong Kong No
5 pA31-12 Escherichia coli 67134 KX034083 China mcr-1
6 pEZE36 Escherichia coli 65846 KY802014 China mcr-1
7 pMRY16-002_4 Escherichia coli 61805 AP017614 Japan mcr-1
8 pMRY15-131_2 Escherichia coli 60722 AP017622 Japan mcr-1
9 pMRY15-117_2 Escherichia coli 61223 AP017619 Japan mcr-1
10 pWF-5-19C_mcr-
1
Cronobacter
sakazakii
65203 KX505142 China mcr-1
11 pVT553 Escherichia coli 62219 KU870627 South
Africa
mcr-1
12 pSCS23 Salmonella enterica 65419 KU934209 China mcr-1
13 pS2.14–2 Escherichia coli 60950 CP016187 Malaysia mcr-1
14 pmcr1_IncI2 Escherichia coli 64964 KU761326 China mcr-1
15 pMCR_1410 Kluyvera ascorbata 57059 KU922754 China mcr-1
16 pEG430-1 Shigella sonnei 61826 LT174530 UK mcr-1
17 pECJS-61-63 Escherichia coli 63656 KX084393 Hong Kong mcr-1
18 pEC13-1 Escherichia coli 60218 CP016186 Malaysia mcr-1
19 pEC5-1 Escherichia coli 61735 CP016185 Malaysia mcr-1
20 pBA77-MCR-1 Escherichia coli 62661 KX013539 Bahrain mcr-1
21 pBA76-MCR-1 Escherichia coli 64942 KX013540 Bahrain mcr-1
22 pAF23 Escherichia coli 61177 KX032519 South
Africa
mcr-1
23 pABC149-MCR-1 Escherichia coli 61228 KX013538 UAE mcr-1
24 pA31-12 Escherichia coli 67134 KX034083 China mcr-1
25 pmcr1_IncI2 Escherichia coli 64964 KU761326 China mcr-1
26 pGN775 Escherichia coli 64600 KY471307 Canada mcr-1
27 pM19855 Escherichia coli 60357 KY471315 Argentina mcr-1
28 pM19441 Escherichia coli 61653 KY471313 Argentina mcr-1
29 pM19242 Escherichia coli 61632 KY471312 Argentina mcr-1
30 pM19736 Escherichia coli 63230 KY471314 Argentina mcr-1
31 pM15224 Escherichia coli 60735 KY471309 Argentina mcr-1
32 pM17059 Escherichia coli 61531 KY471310 Argentina mcr-1.5
33 pM19241 Escherichia coli 61584 KY471311 Argentina mcr-1.5
34 pM15049 Escherichia coli 61198 KY471308 Argentina mcr-1.5
35 pHNSHP45 Escherichia coli 64015 KP347127 China mcr-1
https://doi.org/10.1371/journal.pone.0180347.t003
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Abundant bibliography supports this presumption: mcr-carrying Enterobacteriaceae are fre-
quently isolated from different animal species such as cattle, chicken, and pigs [4,41]. Morax-
ella spp., which includes different species that are mainly animal pathogens, were identified
very recently as potential natural reservoir of chromosomal mcr-like genes, mobilizing them to
Enterobacteriaceae [42]. Detection of mcr-1 also in river water, vegetables and wild birds [43–
45] should impulse more collaborative studies with a One Health perspective to bring light
to this complex matter. In addition, strong restrictions to the use of antimicrobials in the agri-
culture sector have to be implemented, particularly for the ones that are still useful drugs for
human disease treatments (such as polymyxins).
In summary, we have characterized pMCRs from the first mcr-1 positive Enterobacteriaceae
described in the Americas, detected in Argentina and Canada. All these clinical E. coli isolates
were not clonally related and were recovered in different years and locations. However, their
pMCRs had high identity among them and other IncI2 pMCRs characterized in other coun-
tries, which strongly suggest that this plasmid-type is playing an important role in spreading
this mechanism of resistance to polymyxins.
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